Kineta News June 28, 2022Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer >> June 28, 2022Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific OfficerJune 17, 2022Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit >> June 17, 2022Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies SummitJune 7, 2022Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity Therapeutics >> June 7, 2022Puget Sound Business Journal: Seattle biotech Kineta to go public in reverse merger deal with Yumanity TherapeuticsJune 6, 2022GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics >> June 6, 2022GeekWire: Seattle biotech Kineta will go public in deal with neurosciences company Yumanity TherapeuticsJune 6, 2022Kineta Announces Reverse Merger with NASDAQ listed Yumanity Therapeutics (YMTX) >> June 6, 2022Kineta Announces Reverse Merger with NASDAQ listed Yumanity Therapeutics (YMTX)May 26, 2022Life Sciences Review Selects Kineta as Top Biotech Startup of 2022 >> May 26, 2022Life Sciences Review Selects Kineta as Top Biotech Startup of 2022May 18, 2022Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022 >> May 18, 2022Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022April 13, 2022Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022 >> April 13, 2022Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022March 21, 2022Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022 >> March 21, 2022Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022February 24, 2022Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference >> February 24, 2022Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual ConferenceJanuary 24, 2022Kineta to Present on the Company’s PiiONEER™ Platform at the 6th Annual Tumor Models for Immuno-oncology Summit >> January 24, 2022Kineta to Present on the Company’s PiiONEER™ Platform at the 6th Annual Tumor Models for Immuno-oncology SummitJanuary 11, 2022Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference >> January 11, 2022Kineta to Present at the H.C. Wainwright Bioconnect Virtual ConferenceDecember 17, 2021Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021 >> December 17, 2021Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021November 29, 2021Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting >> November 29, 2021Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingNovember 16, 2021Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual Meeting >> November 16, 2021Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual MeetingOctober 7, 2021Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy >> October 7, 2021Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and ImmunotherapySeptember 28, 2021Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy >> September 28, 2021Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and ImmunotherapySeptember 25, 2021Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference >> September 25, 2021Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment ConferenceAugust 10, 2021Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506 >> August 10, 2021Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506July 27, 2021Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1 >> July 27, 2021Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1July 20, 2021Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody >> July 20, 2021Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA AntibodyJuly 14, 2021Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 >> July 14, 2021Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506June 24, 2021Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA >> June 24, 2021Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTAJune 7, 2021Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium >> June 7, 2021Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual SymposiumApril 12, 2021Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021 >> April 12, 2021Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021March 25, 2021Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR) >> March 25, 2021Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)March 3, 2021Kineta Presenting at Multiple Investor Conferences in March 2021 >> March 3, 2021Kineta Presenting at Multiple Investor Conferences in March 2021December 15, 2020Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain >> December 15, 2020Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic PainDecember 9, 2020Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies >> December 9, 2020Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist AntibodiesNovember 12, 2020Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies >> November 12, 2020Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist AntibodiesOctober 20, 2020Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and Immunotherapy >> October 20, 2020Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and ImmunotherapyOctober 8, 2020Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid >> October 8, 2020Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-OpioidOctober 2, 2020Kineta to Participate in BIO Investor Forum Digital >> October 2, 2020Kineta to Participate in BIO Investor Forum DigitalSeptember 23, 2020Kineta Listed in Nature BioPharma Dealmakers of 2020 >> September 23, 2020Kineta Listed in Nature BioPharma Dealmakers of 2020September 15, 2020Pharma Tech Outlook Top 10 Immunotherapy Companies 2020 >> September 15, 2020Pharma Tech Outlook Top 10 Immunotherapy Companies 2020September 11, 2020Kineta to Present at September 2020 Virtual Investor Conferences >> September 11, 2020Kineta to Present at September 2020 Virtual Investor ConferencesAugust 31, 2020Kineta Named Immunotherapy Company of the Year by Pharma Tech Outlook >> August 31, 2020Kineta Named Immunotherapy Company of the Year by Pharma Tech OutlookAugust 12, 2020Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506 >> August 12, 2020Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506July 30, 2020Kineta Invited to Present at August 2020 Investor Conferences >> July 30, 2020Kineta Invited to Present at August 2020 Investor ConferencesJuly 3, 2020Kineta to Present at July 2020 Virtual Investor Events >> July 3, 2020Kineta to Present at July 2020 Virtual Investor EventsMay 20, 2020Shawn Iadonato Named as One of the Top 50 Healthcare Technology CEOs of 2020 >> May 20, 2020Shawn Iadonato Named as One of the Top 50 Healthcare Technology CEOs of 2020May 13, 2020Seattle Biotech CEO Keeps A Watchful Eye on the Market for Potential IPO >> May 13, 2020Seattle Biotech CEO Keeps A Watchful Eye on the Market for Potential IPOMay 5, 2020Kineta Closes Investment Round to Advance Early Preclinical Development of Immuno-oncology Programs >> May 5, 2020Kineta Closes Investment Round to Advance Early Preclinical Development of Immuno-oncology ProgramsApril 21, 2020Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board >> April 21, 2020Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory BoardMarch 25, 2020Kineta to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference >> March 25, 2020Kineta to Present at the Upcoming 2020 Solebury Trout Virtual Investor ConferenceFebruary 28, 2020Kineta Invited to Participate at the Opal Group’s Family Office Winter Forum in New York >> February 28, 2020Kineta Invited to Participate at the Opal Group’s Family Office Winter Forum in New YorkFebruary 27, 2020Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care Conference >> February 27, 2020Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care ConferenceFebruary 5, 2020Kineta Invited to Participate at the BIO CEO & Investor Conference >> February 5, 2020Kineta Invited to Participate at the BIO CEO & Investor ConferenceNovember 26, 2019Kineta Invited to Participate at the 2nd Annual Evercore ISI HealthCONx Conference >> November 26, 2019Kineta Invited to Participate at the 2nd Annual Evercore ISI HealthCONx ConferenceOctober 7, 2019Kineta Invited to Participate at October 2019 Investor Conferences >> October 7, 2019Kineta Invited to Participate at October 2019 Investor ConferencesSeptember 17, 2019After a run of CTLA-4 combo failures, scientists spotlight a way to make it work — in select patients >> September 17, 2019After a run of CTLA-4 combo failures, scientists spotlight a way to make it work — in select patientsAugust 29, 2019Kineta Invited to Participate at the H.C. Wainwright 21st Annual Global Investment Conference >> August 29, 2019Kineta Invited to Participate at the H.C. Wainwright 21st Annual Global Investment ConferenceAugust 21, 2019Kineta Acquires Translation Fund Award $1.8 Million from Welcome Trusts >> August 21, 2019Kineta Acquires Translation Fund Award $1.8 Million from Welcome TrustsAugust 12, 2019Kineta Invited to Participate at Solebury Trout’s 9th Annual CEO Roundtable Conference >> August 12, 2019Kineta Invited to Participate at Solebury Trout’s 9th Annual CEO Roundtable ConferenceAugust 6, 2019Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535 >> August 6, 2019Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535July 15, 2019Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses >> July 15, 2019Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in ArenavirusesJune 24, 2019Local drug makers race to develop non-opioid pain medication >> June 24, 2019Local drug makers race to develop non-opioid pain medicationJune 24, 2019Kineta in the News with Molly Shen on KOMO News >> June 24, 2019Kineta in the News with Molly Shen on KOMO NewsJune 21, 2019Despite Potential to Thrive, Seattle Struggles to Get Biotech Talent >> June 21, 2019Despite Potential to Thrive, Seattle Struggles to Get Biotech TalentMay 28, 2019Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference >> May 28, 2019Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences ConferenceApril 16, 2019Vote for Your Favorite Health Innovation of the Year, a New Category at Geekwire Awards >> April 16, 2019Vote for Your Favorite Health Innovation of the Year, a New Category at Geekwire AwardsMarch 29, 2019Kineta Invited to Present at the 2019 Life Science Innovation Northwest Conference >> March 29, 2019Kineta Invited to Present at the 2019 Life Science Innovation Northwest ConferenceFebruary 26, 2019Innovators: Shawn Iadonato is preparing Kineta to go public this year >> February 26, 2019Innovators: Shawn Iadonato is preparing Kineta to go public this yearFebruary 26, 2019Curt Blake, Amy Morgan and Gene Farrell among PSBJ Innovators of the Year for 2019 >> February 26, 2019Curt Blake, Amy Morgan and Gene Farrell among PSBJ Innovators of the Year for 2019December 17, 2018Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies >> December 17, 2018Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer ImmunotherapiesSeptember 19, 2018Venoms to the Rescue >> September 19, 2018Venoms to the RescueSeptember 11, 2018Immuno-oncology “Set to Become the Fifth Pillar of Cancer Treatment” >> September 11, 2018Immuno-oncology “Set to Become the Fifth Pillar of Cancer Treatment”September 5, 2018Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever >> September 5, 2018Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa FeverAugust 28, 2018Designating Additions to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act >> August 28, 2018Designating Additions to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic ActAugust 23, 2018FDA Adds 4 Diseases to Tropical Diseases Priority Review Voucher Program >> August 23, 2018FDA Adds 4 Diseases to Tropical Diseases Priority Review Voucher ProgramAugust 23, 2018Lassa fever, chikungunya, rabies, and cryptococcal meningitis added to FDA tropical diseases list >> August 23, 2018Lassa fever, chikungunya, rabies, and cryptococcal meningitis added to FDA tropical diseases listJune 29, 2018Increased Development of Non-Opioid Pain Treatments is Expected to Continue >> June 29, 2018Increased Development of Non-Opioid Pain Treatments is Expected to ContinueMay 7, 2018Drug Makers Developing Non-Opioid Pain Alternatives to Battle the Opioid Epidemic >> May 7, 2018Drug Makers Developing Non-Opioid Pain Alternatives to Battle the Opioid EpidemicApril 30, 2018Kineta Developing Non-Opioid Pain Drug That Does More Than Just “Mask” the Problem >> April 30, 2018Kineta Developing Non-Opioid Pain Drug That Does More Than Just “Mask” the ProblemApril 16, 2018Kineta starts drug development collaboration with Genentech >> April 16, 2018Kineta starts drug development collaboration with GenentechApril 16, 2018Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech >> April 16, 2018Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with GenentechApril 16, 2018Seattle biotech Kineta teams up with Genentech to create chronic pain medicine >> April 16, 2018Seattle biotech Kineta teams up with Genentech to create chronic pain medicineApril 16, 2018Kineta signs multi-million dollar collaboration with Genentech to develop non-opioid pain medication >> April 16, 2018Kineta signs multi-million dollar collaboration with Genentech to develop non-opioid pain medicationApril 16, 2018Kineta inks $360 million-plus deal with Genentech for chronic pain drug >> April 16, 2018Kineta inks $360 million-plus deal with Genentech for chronic pain drugApril 16, 2018Roche partners with Kineta to develop non-opioid pain therapy >> April 16, 2018Roche partners with Kineta to develop non-opioid pain therapyApril 16, 2018Genentech, Kineta to Partner on Non-Opioid Pain Treatments >> April 16, 2018Genentech, Kineta to Partner on Non-Opioid Pain TreatmentsApril 16, 2018NAChR average pain drug, Kineta bid bags Genentech deal for as much as $359M+ >> April 16, 2018NAChR average pain drug, Kineta bid bags Genentech deal for as much as $359M+April 16, 2018Kineta, Roche’s Genentech strike chronic pain deal >> April 16, 2018Kineta, Roche’s Genentech strike chronic pain dealApril 16, 2018Kineta inks $360 million-plus deal with Genentech for chronic pain drug >> April 16, 2018Kineta inks $360 million-plus deal with Genentech for chronic pain drugApril 16, 2018Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech >> April 16, 2018Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with GenentechApril 5, 2018Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models >> April 5, 2018Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor ModelsMarch 23, 2018Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference >> March 23, 2018Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations ConferenceMarch 12, 2018Non-addictive Cone Snail Therapy Could Help with Chronic Pain, Crains >> March 12, 2018Non-addictive Cone Snail Therapy Could Help with Chronic Pain, CrainsJanuary 22, 2018Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference >> January 22, 2018Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World ConferenceJanuary 2, 2018Kineta Appoints Michael Banks as New Chief Financial Officer >> January 2, 2018Kineta Appoints Michael Banks as New Chief Financial OfficerSeptember 25, 2017Seattle biotech company developing non-opioid painkiller, King 5 News >> September 25, 2017Seattle biotech company developing non-opioid painkiller, King 5 NewsSeptember 6, 2017Inside Perspectives: Will Immunotherapy Knock Out Cancer? >> September 6, 2017Inside Perspectives: Will Immunotherapy Knock Out Cancer?September 2, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato >> September 2, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn IadonatoAugust 9, 2017Prospects Identified for Iimmunotherapy Treatments >> August 9, 2017Prospects Identified for Iimmunotherapy TreatmentsJune 20, 2017VIDEO: Non-addictive painkiller, KIRO 7 >> June 20, 2017VIDEO: Non-addictive painkiller, KIRO 7June 20, 2017Seattle drug company working on non-addictive, non-opioid painkiller, MyNorthwest >> June 20, 2017Seattle drug company working on non-addictive, non-opioid painkiller, MyNorthwestJune 19, 2017Inside Perspectives: Will Immunotherapy Knock Out Cancer?, WuXi AppTec >> June 19, 2017Inside Perspectives: Will Immunotherapy Knock Out Cancer?, WuXi AppTecJune 12, 2017Kineta to Present at Symposium on Pandemic Preparedness >> June 12, 2017Kineta to Present at Symposium on Pandemic PreparednessMay 15, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato, WuXi AppTec >> May 15, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato, WuXi AppTecMay 15, 2017The Hunt For Non-Opioid, Non-Addictive Painkillers, American Council on Science and Health >> May 15, 2017The Hunt For Non-Opioid, Non-Addictive Painkillers, American Council on Science and HealthMay 4, 2017RLR Agonists Seen to Promote Immune Response Against Colon Cancer Cells in Early Study, Colon Cancer News Today >> May 4, 2017RLR Agonists Seen to Promote Immune Response Against Colon Cancer Cells in Early Study, Colon Cancer News TodayApril 25, 2017Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain >> April 25, 2017Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of PainApril 21, 2017Kineta to Present at the Planet MicroCap Showcase 2017 >> April 21, 2017Kineta to Present at the Planet MicroCap Showcase 2017April 4, 2017Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry Conference >> April 4, 2017Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry ConferenceApril 3, 2017Local company Kineta develops treatment for Lassa fever >> April 3, 2017Local company Kineta develops treatment for Lassa feverMarch 23, 2017Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model >> March 23, 2017Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma ModelMarch 4, 2017A little mollusk may lead to a big discovery in helping solve the U.S. opioid epidemic >> March 4, 2017A little mollusk may lead to a big discovery in helping solve the U.S. opioid epidemicFebruary 22, 2017KCP-400 Relieves Chronic Pain and Demonstrates Disease Modifying Effects >> February 22, 2017KCP-400 Relieves Chronic Pain and Demonstrates Disease Modifying EffectsFebruary 22, 2017Biotech startup tries unique weapon in fight against chronic pain and opioid addiction: snail venom >> February 22, 2017Biotech startup tries unique weapon in fight against chronic pain and opioid addiction: snail venomFebruary 22, 2017Biggest Northwest angel group Keiretsu details its top Seattle-area investments >> February 22, 2017Biggest Northwest angel group Keiretsu details its top Seattle-area investmentsFebruary 21, 2017Snail venom compound ‘offers chronic pain therapy >> February 21, 2017Snail venom compound ‘offers chronic pain therapyJanuary 6, 2017Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San Francisco >> January 6, 2017Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San FranciscoOctober 31, 2016Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum >> October 31, 2016Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor ForumOctober 19, 2016Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum >> October 19, 2016Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor ForumAugust 18, 2016UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATE >> August 18, 2016UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATEAugust 5, 2016As millions visit Rio Olympics, a lack of funding leaves Zika researchers in the dark, GeekWire >> August 5, 2016As millions visit Rio Olympics, a lack of funding leaves Zika researchers in the dark, GeekWireJuly 31, 2016Kineta Secures NIAID Funding to Expand Testing of Immune Modulators >> July 31, 2016Kineta Secures NIAID Funding to Expand Testing of Immune ModulatorsMay 16, 2016Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual Meeting >> May 16, 2016Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual MeetingMay 11, 2016Kineta wins $7.2M award to develop antiviral drug focused on Lassa fever, GeekWire >> May 11, 2016Kineta wins $7.2M award to develop antiviral drug focused on Lassa fever, GeekWireMay 5, 2016Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials >> May 5, 2016Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical TrialsMay 5, 2016Seattle biotech Kineta wins $7.2M award for drug development, Puget Sound Business Journal >> May 5, 2016Seattle biotech Kineta wins $7.2M award for drug development, Puget Sound Business JournalApril 22, 2016Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals >> April 22, 2016Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune AntiviralsMarch 31, 2016Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic Flu >> March 31, 2016Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic FluMarch 22, 2016Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress >> March 22, 2016Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congressload more
